AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia

J. Dunne; D. Mannari; T. Farzaneh; A. Gessner; F. W. Van Delft; O. Heidenreich; B. D. Young; D. M. Gascoyne

doi:10.1038/leu.2011.316

AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia

J. Dunne, D. Mannari, T. Farzaneh, A. Gessner, F. W. Van Delft, O. Heidenreich, B. D. Young, D. M. Gascoyne

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

10 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	1131-1135
Aantal pagina's	5
Tijdschrift	Leukemia
Volume	26
Nummer van het tijdschrift	5
DOI's	https://doi.org/10.1038/leu.2011.316
Status	Gepubliceerd - mei 2012
Extern gepubliceerd	Ja

Toegang tot document

10.1038/leu.2011.316

Citeer dit

@article{856545d59ee24ab2a0bc20064b05e0fa,

title = "AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia",

author = "J. Dunne and D. Mannari and T. Farzaneh and A. Gessner and {Van Delft}, {F. W.} and O. Heidenreich and Young, {B. D.} and Gascoyne, {D. M.}",

note = "Funding Information: 1Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece; 2Laboratory of B cell Neoplasia and Unit of Lymphoid Malignancies, Division of Molecular Oncology, Department of Onco-Hematology and MAGIC (Microenvironment and Genes in Cancers of the blood) Interdivisional Research Program, Istituto Scientifico San Raffaele and Universit{\`a} Vita-Salute San Raffaele, Milano, Italy; 3School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece; 4Institute of Agrobiotechnology, Center for Research and Technology Hellas, Thessaloniki, Greece; 5Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Upssala, Sweden; 6IMGT, the international ImMunoGeneTics information system, Universit{\'e} Montpellier 2, Laboratoire d{\textquoteright}ImmunoG{\'e}n{\'e}tique Mol{\'e}culaire LIGM, UPR CNRS 1142, Montpellier, France; 7Department of Hematooncology, University Hospital Brno, and Central European Institute of Technology, Masaryk University, Brno, Czech Republic; 8Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK; 9Department of Haematology, Imperial College Academic Health Science Centre, Hammersmith Hospital, London, UK; 10CERMS, S. Giovanni Battista Hospital, Turin; Italy; 11Department of Hematology, Rigshospitalet, Copenhagen, Denmark; 12Pathology Unit and Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy; 13Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway; 14Hematology Department, Nikea General Hospital, Athens, Greece and 15Laboratory of Hematology and Universit{\'e} Pierre et Marie Curie, H{\^o}pital Piti{\'e}-Salp{\`e}tri{\`e}re, Paris, France E-mail: [email protected] {Deceased. 16Equal first authors. 17Equal senior authors.",

year = "2012",

month = may,

doi = "10.1038/leu.2011.316",

language = "English",

volume = "26",

pages = "1131--1135",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "5",

}

TY - JOUR

T1 - AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia

AU - Dunne, J.

AU - Mannari, D.

AU - Farzaneh, T.

AU - Gessner, A.

AU - Van Delft, F. W.

AU - Heidenreich, O.

AU - Young, B. D.

AU - Gascoyne, D. M.

N1 - Funding Information: 1Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece; 2Laboratory of B cell Neoplasia and Unit of Lymphoid Malignancies, Division of Molecular Oncology, Department of Onco-Hematology and MAGIC (Microenvironment and Genes in Cancers of the blood) Interdivisional Research Program, Istituto Scientifico San Raffaele and Università Vita-Salute San Raffaele, Milano, Italy; 3School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece; 4Institute of Agrobiotechnology, Center for Research and Technology Hellas, Thessaloniki, Greece; 5Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Upssala, Sweden; 6IMGT, the international ImMunoGeneTics information system, Université Montpellier 2, Laboratoire d’ImmunoGénétique Moléculaire LIGM, UPR CNRS 1142, Montpellier, France; 7Department of Hematooncology, University Hospital Brno, and Central European Institute of Technology, Masaryk University, Brno, Czech Republic; 8Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK; 9Department of Haematology, Imperial College Academic Health Science Centre, Hammersmith Hospital, London, UK; 10CERMS, S. Giovanni Battista Hospital, Turin; Italy; 11Department of Hematology, Rigshospitalet, Copenhagen, Denmark; 12Pathology Unit and Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy; 13Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway; 14Hematology Department, Nikea General Hospital, Athens, Greece and 15Laboratory of Hematology and Université Pierre et Marie Curie, Hôpital Pitié-Salpètrière, Paris, France E-mail: [email protected] {Deceased. 16Equal first authors. 17Equal senior authors.

PY - 2012/5

Y1 - 2012/5

UR - http://www.scopus.com/inward/record.url?scp=84860729659&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.316

DO - 10.1038/leu.2011.316

M3 - Letter

C2 - 22064348

AN - SCOPUS:84860729659

SN - 0887-6924

VL - 26

SP - 1131

EP - 1135

JO - Leukemia

JF - Leukemia

IS - 5

ER -